TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

Benzinga · 2d ago
TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $220.